



Clinical trial results:

A Two-Part Seamless, Multi-Center, Randomized, Placebo-Controlled, Double Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy Patients

Summary

EudraCT number	2016-000750-35
Trial protocol	ES GB IT BE DE FR PL HR BG
Global end of trial date	02 October 2023

Results information

Result version number	v2 (current)
This version publication date	17 April 2024
First version publication date	13 September 2020
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	BP39055
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02908685
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002070-PIP01-16
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 October 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	02 October 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Part 1: To evaluate the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of risdiplam in subjects with Type 2 and Type 3 (ambulant or non-ambulant) SMA, and to select the dose for Part 2 of the study;

Part 2: To evaluate efficacy of risdiplam compared to placebo in terms of motor function in Type 2 and non-ambulant Type 3 SMA subjects, as assessed by the change from baseline in the total score of the Motor Function Measure (MFM) at 12 months

Protection of trial subjects:

All study subjects, parent or legal guardian were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 October 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 19
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	France: 25
Country: Number of subjects enrolled	Italy: 51
Country: Number of subjects enrolled	Brazil: 2
Country: Number of subjects enrolled	Canada: 18
Country: Number of subjects enrolled	China: 16
Country: Number of subjects enrolled	Spain: 21
Country: Number of subjects enrolled	Croatia: 11
Country: Number of subjects enrolled	Japan: 15
Country: Number of subjects enrolled	Poland: 32
Country: Number of subjects enrolled	Russian Federation: 4
Country: Number of subjects enrolled	Serbia: 8
Country: Number of subjects enrolled	Türkiye: 1
Country: Number of subjects enrolled	United States: 4
Worldwide total number of subjects	231
EEA total number of subjects	163

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	143
Adolescents (12-17 years)	62
Adults (18-64 years)	26
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study Part 1 was conducted at 5 investigational sites across 4 countries, and Part 2 was conducted at 42 investigational sites across 14 countries. Screening in both Part 1 and 2 was up to 30 days prior to first dose.

Pre-assignment

Screening details:

In Part 1 participants were initially enrolled by age and in a dose-escalating design; each group included participants on active and placebo treatment in a 2:1 ratio. After Part 2 dose selection the study enrolled additional participants in a 2:1 ratio in Part 2.

Period 1

Period 1 title	Part 1 and 2 Placebo-Controlled
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 1 Group A Cohort 1: Adolescents/Adults (3 mg Risdiplam)

Arm description:

Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Part 1 was a dose-finding exploratory part. Risdiplam, 3 mg was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 1 Group A Cohort 2: Adolescents/Adults (5 mg Risdiplam)
------------------	--

Arm description:

Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Part 1 was a dose-finding exploratory part. Risdiplam, 5 mg was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 1 Group A Cohort 1: Adolescents/Adults (Placebo)
<p>Arm description:</p> <p>Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 3 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</p>	
Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use
<p>Dosage and administration details:</p> <p>Part 1 was a dose-finding exploratory part. Risdiplam matching placebo was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam matching placebo orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam matching placebo by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.</p>	
Arm title	Part 1 Group A Cohort 2: Adolescents/Adults (Placebo)
<p>Arm description:</p> <p>Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 5 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</p>	
Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use
<p>Dosage and administration details:</p> <p>Part 1 was a dose-finding exploratory part. Risdiplam matching placebo was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam matching placebo orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam matching placebo by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.</p>	
Arm title	Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam)
<p>Arm description:</p> <p>Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.05 mg/kg and then to 0.15 mg/kg in two steps. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.</p>	
Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use
<p>Dosage and administration details:</p> <p>Part 1 was a dose-finding exploratory part. Risdiplam, 0.02 mg/kg was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.</p>	
Arm title	Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam)

Arm description:

Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.15 mg/kg in one step. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Part 1 was a dose-finding exploratory part. Risdiplam, 0.05 mg/kg was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam)
------------------	--

Arm description:

Children aged 2-11 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Part 1 was a dose-finding exploratory part. Risdiplam, 0.25 mg/kg was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 1 Group B Cohort 1: Children (Placebo)
------------------	---

Arm description:

Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Part 1 was a dose-finding exploratory part. Risdiplam matching placebo was administered once daily with meal orally or through gastric tube. Subjects receiving risdiplam matching placebo orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam matching placebo by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 1 Group B Cohort 2: Children (Placebo)
------------------	---

Arm description:

Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Part 1 was a dose-finding exploratory part. Risdipram matching placebo was administered once daily with meal orally or through gastric tube.

Subjects receiving risdipram matching placebo orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdipram matching placebo by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 1 Group B Cohort 3: Children (Placebo)
------------------	---

Arm description:

Children aged 2-11 years received placebo matching to risdipram for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Part 1 was a dose-finding exploratory part. Risdipram matching placebo was administered once daily with meal orally or through gastric tube.

Subjects receiving risdipram matching placebo orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdipram matching placebo by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 2: Risdipram
------------------	-------------------

Arm description:

Participants aged 2-25 years received risdipram at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months. Once the Part 2 placebo-controlled period was completed participants received risdipram at the same dose level for another 12 months (Month 12-24) in the open-label treatment (OLT) phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdipram at the same dose level.

Arm type	Experimental
Investigational medicinal product name	risdipram
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Risdipram was administered once daily with meal orally or through gastric tube at 5 mg for subjects with body weight (BW) ≥ 20 kg and 0.25 mg/kg for subjects with BW < 20 kg. Subjects receiving risdipram orally followed this by rinsing their mouth with water and swallowing.

Subjects unable to swallow were to receive risdipram by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 2: Placebo
------------------	-----------------

Arm description:

Participants aged 2-25 years received placebo matching to risdipram for 12 months. After 12 months of treatment with placebo, participants switched to risdipram (5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20) in a blinded manner in the OLT phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdipram at

the same dose level.

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Risdiplam matching placebo was administered once daily with meal orally or through gastric tube.

Subjects receiving risdiplam matching placebo orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam matching placebo by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Number of subjects in period 1	Part 1 Group A Cohort 1: Adolescents/Adults (3 mg Risdiplam)	Part 1 Group A Cohort 2: Adolescents/Adults (5 mg Risdiplam)	Part 1 Group A Cohort 1: Adolescents/Adults (Placebo)
Started	7	7	3
Completed	7	7	3
Not completed	0	0	0
Changed to other treatment	-	-	-
Changed to Spinraza	-	-	-

Number of subjects in period 1	Part 1 Group A Cohort 2: Adolescents/Adults (Placebo)	Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam)	Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam)
Started	3	7	7
Completed	3	7	7
Not completed	0	0	0
Changed to other treatment	-	-	-
Changed to Spinraza	-	-	-

Number of subjects in period 1	Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam)	Part 1 Group B Cohort 1: Children (Placebo)	Part 1 Group B Cohort 2: Children (Placebo)
Started	7	3	4
Completed	7	3	4
Not completed	0	0	0
Changed to other treatment	-	-	-
Changed to Spinraza	-	-	-

Number of subjects in period 1	Part 1 Group B Cohort 3: Children (Placebo)	Part 2: Risdiplam	Part 2: Placebo
Started	3	120	60
Completed	3	117	59
Not completed	0	3	1

Changed to other treatment	-	1	-
Changed to Spinraza	-	2	1

Period 2

Period 2 title	Part 1 OLE and Part 2 OLT
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 1 Group A: OLE

Arm description:

Once the placebo-controlled period was completed and Part 2 dose was selected, adolescents and adults switched to Part 2 dose and were treated in an open-label extension (OLE) phase.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Risdiplam was administered once daily with meal orally or through gastric tube at 5 mg for subjects with body weight (BW) ≥ 20 kg and 0.25 mg/kg for subjects with BW < 20 kg. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 1 Group B: OLE
------------------	---------------------

Arm description:

Once the placebo-controlled period was completed and Part 2 dose was selected, children switched to Part 2 dose and were treated in an open-label extension (OLE) phase.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Risdiplam was administered once daily with meal orally or through gastric tube at 5 mg for subjects with body weight (BW) ≥ 20 kg and 0.25 mg/kg for subjects with BW < 20 kg. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 2: Risdiplam/Risdiplam OLT
------------------	---------------------------------

Arm description:

Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months. Once the Part 2 placebo-controlled period was completed participants received risdiplam at the same dose level for another 12 months (Month 12-24) in the open-label treatment (OLT) phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Risdiplam was administered once daily with meal orally or through gastric tube at 5 mg for subjects with body weight (BW) ≥ 20 kg and 0.25 mg/kg for subjects with BW < 20 kg. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 2: Placebo/Risdiplam OLT
------------------	-------------------------------

Arm description:

Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20) in a blinded manner in the OLT phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution, Powder for oral solution
Routes of administration	Oral use, Oral use

Dosage and administration details:

Risdiplam was administered once daily with meal orally or through gastric tube at 5 mg for subjects with body weight (BW) ≥ 20 kg and 0.25 mg/kg for subjects with BW < 20 kg. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Number of subjects in period 2	Part 1 Group A: OLE	Part 1 Group B: OLE	Part 2: Risdiplam/Risdiplam OLT
Started	20	31	117
Completed	18	30	116
Not completed	2	1	1
Consent withdrawn by subject	2	1	1

Number of subjects in period 2	Part 2: Placebo/Risdiplam OLT
---------------------------------------	-------------------------------------

Started	59
Completed	59
Not completed	0
Consent withdrawn by subject	-

Period 3

Period 3 title	Part 2 OLE
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part 2: RisdiplamRisdiplam OLE

Arm description:

Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months. Once the Part 2 placebo-controlled period was completed participants received risdiplam at the same dose level for another 12 months (Month 12-24) in the open-label treatment (OLT) phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Risdiplam was administered once daily with meal orally or through gastric tube at 5 mg for subjects with body weight (BW) ≥ 20 kg and 0.25 mg/kg for subjects with BW < 20 kg. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Arm title	Part 2: Placebo/Risdiplam OLE
------------------	-------------------------------

Arm description:

Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20) in a blinded manner in the OLT phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Arm type	Experimental
Investigational medicinal product name	risdiplam
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Risdiplam was administered once daily with meal orally or through gastric tube at 5 mg for subjects with body weight (BW) ≥ 20 kg and

0.25 mg/kg for subjects with BW <20 kg. Subjects receiving risdiplam orally followed this by rinsing their mouth with water and swallowing. Subjects unable to swallow were to receive risdiplam by bolus via their naso-gastric or gastrostomy tube. This was followed by a bolus flush of water through the tube.

Number of subjects in period 3^[1]	Part 2: RisdiplamRisdiplam OLE	Part 2: Placebo/Risdiplam OLE
Started	116	59
Completed	103	53
Not completed	13	6
Consent withdrawn by subject	10	5
Death	1	-
Reason not specified	2	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only Part 2 participants progressed to the final period.

Baseline characteristics

Reporting groups

Reporting group title	Part 1 Group A Cohort 1: Adolescents/Adults (3 mg Risdiplam)
-----------------------	--

Reporting group description:

Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group A Cohort 2: Adolescents/Adults (5 mg Risdiplam)
-----------------------	--

Reporting group description:

Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group A Cohort 1: Adolescents/Adults (Placebo)
-----------------------	---

Reporting group description:

Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 3 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group A Cohort 2: Adolescents/Adults (Placebo)
-----------------------	---

Reporting group description:

Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 5 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam)
-----------------------	--

Reporting group description:

Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.05 mg/kg and then to 0.15 mg/kg in two steps. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam)
-----------------------	--

Reporting group description:

Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.15 mg/kg in one step. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam)
-----------------------	--

Reporting group description:

Children aged 2-11 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group B Cohort 1: Children (Placebo)
-----------------------	---

Reporting group description:

Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group B Cohort 2: Children (Placebo)
-----------------------	---

Reporting group description:

Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 1 Group B Cohort 3: Children (Placebo)
-----------------------	---

Reporting group description:

Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to

Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 2: Risdiplam
Reporting group description:	
Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months. Once the Part 2 placebo-controlled period was completed participants received risdiplam at the same dose level for another 12 months (Month 12-24) in the open-label treatment (OLT) phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.	

Reporting group title	Part 2: Placebo
Reporting group description:	
Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20) in a blinded manner in the OLT phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.	

Reporting group values	Part 1 Group A Cohort 1: Adolescents/Adults (3 mg Risdiplam)	Part 1 Group A Cohort 2: Adolescents/Adults (5 mg Risdiplam)	Part 1 Group A Cohort 1: Adolescents/Adults (Placebo)
Number of subjects	7	7	3
Age categorical			
Units: Subjects			

Age Continuous			
Units: Years			
arithmetic mean	13.3	18.1	14.7
standard deviation	± 1.1	± 4.6	± 1.5
Sex: Female, Male			
Units: Participants			
Female	5	5	1
Male	2	2	2

Reporting group values	Part 1 Group A Cohort 2: Adolescents/Adults (Placebo)	Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam)	Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam)
Number of subjects	3	7	7
Age categorical			
Units: Subjects			

Age Continuous			
Units: Years			
arithmetic mean	17.3	6.1	4.3
standard deviation	± 5.1	± 2.9	± 1.7
Sex: Female, Male			
Units: Participants			
Female	2	5	3
Male	1	2	4

Reporting group values	Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam)	Part 1 Group B Cohort 1: Children (Placebo)	Part 1 Group B Cohort 2: Children (Placebo)
Number of subjects	7	3	4

Age categorical Units: Subjects			
Age Continuous Units: Years arithmetic mean standard deviation	6.0 ± 2.7	5.3 ± 2.1	3.5 ± 0.6
Sex: Female, Male Units: Participants			
Female	4	0	2
Male	3	3	2

Reporting group values	Part 1 Group B Cohort 3: Children (Placebo)	Part 2: Risdiplam	Part 2: Placebo
Number of subjects	3	120	60
Age categorical Units: Subjects			

Age Continuous Units: Years arithmetic mean standard deviation	5.3 ± 2.9	9.9 ± 5.8	10.3 ± 6.0
Sex: Female, Male Units: Participants			
Female	0	61	30
Male	3	59	30

Reporting group values	Total		
Number of subjects	231		
Age categorical Units: Subjects			

Age Continuous Units: Years arithmetic mean standard deviation	-		
Sex: Female, Male Units: Participants			
Female	118		
Male	113		

End points

End points reporting groups

Reporting group title	Part 1 Group A Cohort 1: Adolescents/Adults (3 mg Risdiplam)
Reporting group description: Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group A Cohort 2: Adolescents/Adults (5 mg Risdiplam)
Reporting group description: Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed and Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group A Cohort 1: Adolescents/Adults (Placebo)
Reporting group description: Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 3 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group A Cohort 2: Adolescents/Adults (Placebo)
Reporting group description: Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to their cohort risdiplam dose (i.e. 5 mg). After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group B Cohort 1: Children (0.02 mg/kg Risdiplam)
Reporting group description: Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.05 mg/kg and then to 0.15 mg/kg in two steps. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group B Cohort 2: Children (0.05 mg/kg Risdiplam)
Reporting group description: Children aged 2-11 years received risdiplam for at least 12 weeks. During the placebo-controlled period, participants escalated to 0.15 mg/kg in one step. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group B Cohort 3: Children (0.25 mg/kg Risdiplam)
Reporting group description: Children aged 2-11 years received risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group B Cohort 1: Children (Placebo)
Reporting group description: Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group B Cohort 2: Children (Placebo)
Reporting group description: Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, participants first switched to the final 0.15 mg/kg cohort risdiplam dose. After the Part 2 dose was selected, participants switched to Part 2 dose and were treated in an open-label phase.	
Reporting group title	Part 1 Group B Cohort 3: Children (Placebo)
Reporting group description: Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks. Once the placebo-controlled period was completed, and after Part 2 dose was selected, participants switched to	

Part 2 dose and were treated in an open-label phase.

Reporting group title	Part 2: Risdiplam
-----------------------	-------------------

Reporting group description:

Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months. Once the Part 2 placebo-controlled period was completed participants received risdiplam at the same dose level for another 12 months (Month 12-24) in the open-label treatment (OLT) phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Reporting group title	Part 2: Placebo
-----------------------	-----------------

Reporting group description:

Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20) in a blinded manner in the OLT phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Reporting group title	Part 1 Group A: OLE
-----------------------	---------------------

Reporting group description:

Once the placebo-controlled period was completed and Part 2 dose was selected, adolescents and adults switched to Part 2 dose and were treated in an open-label extension (OLE) phase.

Reporting group title	Part 1 Group B: OLE
-----------------------	---------------------

Reporting group description:

Once the placebo-controlled period was completed and Part 2 dose was selected, children switched to Part 2 dose and were treated in an open-label extension (OLE) phase.

Reporting group title	Part 2: Risdiplam/Risdiplam OLT
-----------------------	---------------------------------

Reporting group description:

Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months. Once the Part 2 placebo-controlled period was completed participants received risdiplam at the same dose level for another 12 months (Month 12-24) in the open-label treatment (OLT) phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Reporting group title	Part 2: Placebo/Risdiplam OLT
-----------------------	-------------------------------

Reporting group description:

Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20) in a blinded manner in the OLT phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Reporting group title	Part 2: RisdiplamRisdiplam OLE
-----------------------	--------------------------------

Reporting group description:

Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months. Once the Part 2 placebo-controlled period was completed participants received risdiplam at the same dose level for another 12 months (Month 12-24) in the open-label treatment (OLT) phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Reporting group title	Part 2: Placebo/Risdiplam OLE
-----------------------	-------------------------------

Reporting group description:

Participants aged 2-25 years received placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants switched to risdiplam (5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20) in a blinded manner in the OLT phase. After Month 24 participants entered the Part 2 OLE phase and continued to receive risdiplam at the same dose level.

Subject analysis set title	Part 1: All Risdiplam
----------------------------	-----------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.

Subject analysis set title	Part 1: All Risdiplam
----------------------------	-----------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.

Subject analysis set title	Part 2: All Risdiplam
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.

Subject analysis set title	Part 2: All Risdiplam
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.

Subject analysis set title	Part 1: All Risdiplam
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.

Subject analysis set title	Part 2: All Risdiplam
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Children aged 2-11 years and adolescent and adult participants aged 12-25 years received risdiplam or risdiplam matching placebo.

Primary: Part 1: Selected Part 2 Dose of Risdiplam for Participants with a Body Weight (BW) of ≥ 20 kg

End point title	Part 1: Selected Part 2 Dose of Risdiplam for Participants with a Body Weight (BW) of ≥ 20 kg ^[1]
-----------------	---

End point description:

The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1. Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC_{0-24h,ss} 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses can be provided for this primary end point.

End point values	Part 1: All Risdiplam			
Subject group type	Subject analysis set			
Number of subjects analysed	51			
Units: milligram (mg)	5			

Statistical analyses

No statistical analyses for this end point

Primary: Part 1: Selected Part 2 Dose of Risdiplam for Participants with BW of <20kg

End point title	Part 1: Selected Part 2 Dose of Risdiplam for Participants with BW of <20kg ^[2]
-----------------	--

End point description:

The Internal Monitoring Committee (IMC) was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1. Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC_{0-24h,ss} 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses can be provided for this primary end point.

End point values	Part 1: All Risdiplam			
Subject group type	Subject analysis set			
Number of subjects analysed	51			
Units: milligram/kilogram (mg/kg)				
number (not applicable)	0.25			

Statistical analyses

No statistical analyses for this end point

Primary: Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12

End point title	Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12 ^[3]
-----------------	---

End point description:

The Motor Function Measure 32 (MFM32) is a scale for neuromuscular disorders. It comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate task or maintain starting position; 1 - performs task partially; 2 - performs task incompletely or imperfectly; 3 - performs task fully and "normally". The 32 scores are summed and expressed on a 0-100 scale for the total score. Higher scores indicate increased motor function. Positive change from Baseline indicates improvement. MMRM analysis was performed based on primary efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and subjects continued on randomized treatment until the analysis time point. ITT population except subjects without MFM32 total score at Baseline.

End point type	Primary
----------------	---------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	115	59		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	1.36 (0.61 to 2.11)	-0.19 (-1.22 to 0.84)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Placebo v Part 2: Risdiplam
Number of subjects included in analysis	174
Analysis specification	Pre-specified
Analysis type	superiority ^[4]
P-value	= 0.0156
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	1.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	2.81

Notes:

[4] - This is the first end point and first family tested in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Percentage of Participants with Marked Improvement (Defined as ≥ 3) in the Total Motor Function Measure (MFM32) Score at Month 12

End point title	Part 2: Percentage of Participants with Marked Improvement (Defined as ≥ 3) in the Total Motor Function Measure (MFM32) Score at Month 12 ^[5]
-----------------	--

End point description:

The MFM32 comprises 32 items that evaluate physical function. The scoring of each task uses a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and "normally". The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. A change in MFM32 total score of threshold ≥ 3 represents marked improvement in this measure. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. ITT population defined as all randomized participants in Part 2. Subjects with missing MFM32 total score at Baseline not included in the analysis. Missing results at Month 12 are considered as non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 12

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	115	59		
Units: Percentage of Participants				
number (confidence interval 95%)	38.3 (28.94 to 47.58)	23.7 (12.03 to 35.43)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	174
Analysis specification	Pre-specified
Analysis type	superiority ^[6]
P-value	= 0.0469 ^[7]
Method	Wald test
Parameter estimate	Odds ratio (OR)
Point estimate	2.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.01
upper limit	5.44

Notes:

[6] - This is the second end point and second family tested in the hierarchical testing. Logistic Regression Model. The variables included in the logistic regression are: baseline total score, treatment and age group.

[7] - Adjusted p-Value

The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.

Secondary: Part 2: Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12

End point title	Part 2: Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12 ^[8]
-----------------	--

End point description:

RULM is a 20 items scale that assesses the proximal and distal motor functions of the arm. There is an entry item and the remaining 18 items are scored on a 3 point scale of: 0: cannot complete task independently; 1: modified method but can complete task independently; 2: completes task without any assistance, and with 1 item scored on a 2 point scale of as a can/cannot score with 1 as the highest score. RULM total score is the sum of 19 items scores with range of 0-37, and the entry item does not contribute to the total score. Higher scores indicate greater upper limb function. Positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. Subjects with missing RULM total score at Baseline not included in analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	119	58		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	1.61 (1.00 to 2.22)	0.02 (-0.83 to 0.87)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	177
Analysis specification	Pre-specified
Analysis type	superiority ^[9]
P-value	= 0.0469 ^[10]
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	1.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	2.62

Notes:

[9] - This is the third end point and third family tested in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

[10] - Adjusted p-Value

The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.

Secondary: Part 2: Change from Baseline in Forced Vital Capacity (FVC) at Month 12 in Participants Aged 6-25 Years

End point title	Part 2: Change from Baseline in Forced Vital Capacity (FVC) at Month 12 in Participants Aged 6-25 Years ^[11]
-----------------	---

End point description:

Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced vital capacity (FVC) is the total volume that can be exhaled after inhaling maximally. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. ITT population defined as all randomized participants in Part 2. Subjects with missing FVC data at Baseline were not included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	40		
Units: Percentage Predicted				
least squares mean (confidence interval 95%)	-5.16 (-7.93 to -2.39)	-3.11 (-6.59 to 0.74)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	123
Analysis specification	Pre-specified
Analysis type	superiority ^[12]
P-value	= 0.3902 ^[13]
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	-2.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.67
upper limit	2.56

Notes:

[12] - This is one of the two end points in family four in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

[13] - Adjusted p-Value

The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.

Secondary: Part 2: Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12

End point title	Part 2: Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12 ^[14]
-----------------	--

End point description:

The HFMSE scale contains 33 items, which are scored on a 3-point Likert-type scale (0-2) and summed to derive the total score, with lower scores indicating greater impairment. The HFMSE contains a series of assessments designed to assess important functional abilities, including standing, transfers, ambulation, and proximal and axial function. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate greater motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on the efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. ITT population defined as all randomized participants in Part 2.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdipram	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	60		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	0.95 (0.29 to 1.61)	0.37 (-0.54 to 1.28)		

Statistical analyses

Statistical analysis title	Part 2: Risdipram versus Placebo
Comparison groups	Part 2: Risdipram v Part 2: Placebo
Number of subjects included in analysis	180
Analysis specification	Pre-specified
Analysis type	superiority ^[15]
P-value	= 0.3902 ^[16]
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	0.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.53
upper limit	1.69

Notes:

[15] - This is one of the two end points in family four in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

[16] - Adjusted p-Value

The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.

Secondary: Part 2: Change from Baseline in the Caregiver-Reported SMA Independence Scale (SMAIS) Total Score at Month 12

End point title	Part 2: Change from Baseline in the Caregiver-Reported SMA Independence Scale (SMAIS) Total Score at Month 12 ^[17]
-----------------	---

End point description:

SMA Independence Scale (SMAIS) was developed specifically for SMA participants in order to assess function-related independence. SMAIS contains 29 items, assessing the amount of assistance required from another individual to perform daily activities. Each item is scored on a 0-4 scale (or as non-applicable). SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on a 0-2 scale. Lower scores indicate greater dependence on another individual. SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. ITT population: all randomized participants in Part 2. Subjects with missing SMAIS total score at Baseline not included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risperidone	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	116	60		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	1.65 (0.66 to 2.63)	-0.91 (-2.23 to 0.42)		

Statistical analyses

Statistical analysis title	Part 2: Risperidone versus Placebo
Comparison groups	Part 2: Risperidone v Part 2: Placebo
Number of subjects included in analysis	176
Analysis specification	Pre-specified
Analysis type	superiority ^[18]
P-value	= 0.3902 ^[19]
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	2.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	4.17

Notes:

[18] - This is the sixth endpoint and the fifth family tested in the hierarchical testing. The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

[19] - Adjusted p-Value

The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.

Secondary: Part 2: Percentage of Participants Rated by Clinicians as Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12

End point title	Part 2: Percentage of Participants Rated by Clinicians as Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12 ^[20]
-----------------	--

End point description:

The Clinical Global Impression of Change (CGI-C) is used to score a clinician's impression of a participant's change in global health. The CGI-C is a single item measure of change in global health, using seven response options: "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", and "very much worse". Participants considered as "improved" included responses of "very much improved", "much improved" and "minimally improved". Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. ITT population: all randomized participants in Part 2. Missing results at Month 12 are considered as non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 12

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	60		
Units: Percentage of Participants				
number (confidence interval 95%)	47.5 (38.15 to 56.86)	40.0 (26.77 to 53.23)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Statistical analysis description: CGI Improved	
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	180
Analysis specification	Pre-specified
Analysis type	superiority ^[21]
P-value	= 0.3902 ^[22]
Method	Wald-test
Parameter estimate	Odds ratio (OR)
Point estimate	1.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	2.74

Notes:

[21] - This is the seventh endpoint and the sixth family tested in the hierarchical testing. Logistic Regression Model. The variables included in the logistic regression are: baseline total score, treatment and age group.

[22] - Adjusted p-Value

The adjusted p-values were derived based on all the p-values from end points in order of the hierarchical testing up to the current endpoint.

Secondary: Part 2: Percentage of Participants who Achieve Stabilization or Improvement (Defined as ≥ 0) in the Total Motor Function Measure (MFM-32) Score at Month 12

End point title	Part 2: Percentage of Participants who Achieve Stabilization or Improvement (Defined as ≥ 0) in the Total Motor Function Measure (MFM-32) Score at Month 12 ^[23]
-----------------	---

End point description:

The MFM32 comprises 32 items that evaluate physical function. The scoring of each task uses a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and "normally". The 32 scores are summed and expressed on a 0-100 scale for the MFM32 total score. A change in MFM32 total score of threshold ≥ 3 represents marked improvement in this measure. Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. ITT population defined as all randomized participants in Part 2. Subjects with missing MFM32 total score at Baseline not included in the analysis. Missing results at Month 12 are considered as non-responders.

End point type	Secondary
End point timeframe:	
At Month 12	
Notes:	
[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: Only Part 2 arms were included in this end point.	

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	115	59		
Units: Percentage of Participants				
number (confidence interval 95%)	69.6 (60.72 to 78.41)	54.2 (40.68 to 67.80)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	174
Analysis specification	Pre-specified
Analysis type	superiority ^[24]
P-value	= 0.043
Method	Wald test
Parameter estimate	Odds ratio (OR)
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.02
upper limit	3.93

Notes:

[24] - Logistic Regression Model. The variables included in the logistic regression are: baseline total score, treatment and age group.

Secondary: Part 2: Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM-32 Score at Month 12

End point title	Part 2: Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM-32 Score at Month 12 ^[25]
-----------------	---

End point description:

The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0-cannot initiate the task or maintain starting position; 1-performs task partially; 2-performs task incompletely or imperfectly; 3-performs task fully and "normally". The 32 scores are summed and expressed on a 0-100 scale for the total score. Higher scores indicate increased motor function. Standard error of measurement (SEM) is derived using 32 items scores and total scores at baseline. Change from baseline \geq one SEM is equivalent to a change ≥ 4 . Logistic regression analysis based on efficacy hypothetical estimand included participants data assuming no prohibited medication intended for treatment of SMA was received and subjects continued on randomized treatment until the analysis time point. ITT population except subjects without MFM32 total score at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 12

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	115	59		
Units: Percentage of Participants				
number (confidence interval 95%)	28.7 (20.65 to 37.88)	16.9 (8.44 to 28.97)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12

End point title	Part 2: Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12 ^[26]
-----------------	--

End point description:

The Sniff Nasal Inspiratory Pressure (SNIP) is a volitional, non-invasive test of inspiratory muscle strength that has been successfully applied to children > 2 years of age. Advantages include the simplicity of the maneuver and the absence of a mouthpiece, which is particularly helpful for participants with SMA, who may have bulbar weakness. SNIP also has the advantage of measuring inspiratory pressure during a natural maneuver that is easily performed even by young children with neuromuscular disorders. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without SNIP data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	59		
Units: Percentage Predicted				
least squares mean (confidence interval 95%)	3.42 (0.22 to 6.62)	1.07 (-3.42 to 5.57)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	177
Analysis specification	Pre-specified
Analysis type	superiority ^[27]
P-value	= 0.3967
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	2.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.11
upper limit	7.8

Notes:

[27] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in the MFM-32 Domain 1 (D1) Score at Month 12

End point title	Part 2: Change from Baseline in the MFM-32 Domain 1 (D1) Score at Month 12 ^[28]
-----------------	--

End point description:

The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and "normally". The D1 items score are summed and expressed on 0-100 scale for the MFM D1 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without MFM32 data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	60		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	0.37 (-0.12 to 0.87)	-0.26 (-0.94 to 0.42)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	178
Analysis specification	Pre-specified
Analysis type	superiority ^[29]
P-value	= 0.1328
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	1.47

Notes:

[29] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in the MFM-32 Domain 2 (D2) Score at Month 12

End point title	Part 2: Change from Baseline in the MFM-32 Domain 2 (D2) Score at Month 12 ^[30]
-----------------	--

End point description:

The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and "normally". The D2 items score are summed and expressed on 0-100 scale for the MFM D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without MFM32 data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	60		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	1.04 (-0.38 to 2.46)	-0.93 (-2.87 to 1.02)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	178
Analysis specification	Pre-specified
Analysis type	superiority ^[31]
P-value	= 0.103
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	1.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	4.34

Notes:

[31] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in the MFM-32 Domain 3 (D3) Score at Month 12

End point title	Part 2: Change from Baseline in the MFM-32 Domain 3 (D3) Score at Month 12 ^[32]
-----------------	--

End point description:

The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and "normally". The D3 items score are summed and expressed on 0-100 scale for the MFM D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without MFM32 data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	115	59		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	3.68 (2.31 to 5.04)	1.34 (-0.54 to 3.22)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	174
Analysis specification	Pre-specified
Analysis type	superiority ^[33]
P-value	= 0.0451
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	2.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.05
upper limit	4.62

Notes:

[33] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in the Total Combined Scores of MFM-32 Domains 1 and 2 at Month 12

End point title	Part 2: Change from Baseline in the Total Combined Scores of MFM-32 Domains 1 and 2 at Month 12 ^[34]
-----------------	---

End point description:

The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and "normally". The D1+D2 items score are summed and expressed on 0-100 scale for the MFM D1+D2 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without MFM32 data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	118	60		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	0.69 (-0.07 to 1.45)	-0.59 (-1.64 to 0.45)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	178
Analysis specification	Pre-specified
Analysis type	superiority ^[35]
P-value	= 0.0489
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	1.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.01
upper limit	2.56

Notes:

[35] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in the Total Combined Scores of MFM-32 Domains 2 and 3 at Month 12

End point title	Part 2: Change from Baseline in the Total Combined Scores of MFM-32 Domains 2 and 3 at Month 12 ^[36]
-----------------	---

End point description:

The MFM32 comprises 32 items that evaluate physical function in three dimensions: D1 function related to standing and transfer; D2 axial and proximal function; D3 distal motor function. Tasks are scored with a 4-point Likert scale: 0 - cannot initiate the task or maintain the starting position; 1 - performs the task partially; 2 - performs the task incompletely or imperfectly; 3 - performs the task fully and "normally". The D2+D3 items score are summed and expressed on 0-100 scale for the MFM D2+D3 total score. Higher scores indicate increased motor function. A positive change from Baseline indicates improvement. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without MFM32 data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	115	59		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	2.02 (0.84 to 3.20)	-0.14 (-1.76 to 1.48)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	174
Analysis specification	Pre-specified
Analysis type	superiority ^[37]
P-value	= 0.0326
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	2.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.18
upper limit	4.14

Notes:

[37] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12 in Participants Aged 6-25 Years

End point title	Part 2: Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12 in Participants Aged 6-25 Years ^[38]
-----------------	---

End point description:

Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Forced expiratory volume (FEV1) is the volume forcefully exhaled in the first second of the forced vital capacity test. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without FEV1 data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	40		
Units: Percentage Predicted				
least squares mean (confidence interval 95%)	-4.22 (-7.49 to -0.96)	-1.35 (-5.91 to 3.20)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo

Number of subjects included in analysis	123
Analysis specification	Pre-specified
Analysis type	superiority ^[39]
P-value	= 0.3029
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	-2.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.36
upper limit	2.62

Notes:

[39] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in the Peak Cough Flow (PCF) at Month 12 in Participants Aged 6-25 Years

End point title	Part 2: Change from Baseline in the Peak Cough Flow (PCF) at Month 12 in Participants Aged 6-25 Years ^[40]
-----------------	---

End point description:

Spirometry is a pulmonary function test that assesses how the lungs work by measuring how much air moves through the airways. Spirometry was performed by all participants aged 6 or older. Peak cough flow (PCF) is an assessment of cough strength. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without PCF data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	42		
Units: Percent Predicted				
least squares mean (confidence interval 95%)	1.06 (-1.18 to 3.31)	-0.22 (-3.27 to 2.83)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo

Number of subjects included in analysis	125
Analysis specification	Pre-specified
Analysis type	superiority ^[41]
P-value	= 0.4937
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	1.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.42
upper limit	4.99

Notes:

[41] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12 in Participants Aged 6-25 Years

End point title	Part 2: Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12 in Participants Aged 6-25 Years ^[42]
-----------------	--

End point description:

The maximal inspiratory pressure (MIP) is a non-invasive test of muscle strength, which measures the maximum strength of the diaphragm and other inspiratory muscles. MIP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without MIP data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	81	40		
Units: Percentage Predicted				
least squares mean (confidence interval 95%)	1.99 (-6.13 to 10.11)	-0.97 (-12.33 to 10.38)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo

Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority ^[43]
P-value	= 0.6704
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	2.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.78
upper limit	16.7

Notes:

[43] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12 in Participants Aged 6-25 Years

End point title	Part 2: Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12 in Participants Aged 6-25 Years ^[44]
-----------------	---

End point description:

The maximal expiratory pressure (MEP) is a non-invasive test of muscle strength, which measures the maximum strength of the abdominal muscles and other expiratory muscles. MEP was measured in participants aged 6 or older. Participants were asked to perform a forceful inspiration against an occluded mouth piece. The best % predicted value out of all attempts were used for the analysis. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without MEP data at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	41		
Units: Percentage Predicted				
least squares mean (confidence interval 95%)	-2.75 (-6.22 to 0.72)	-2.33 (-7.21 to 2.56)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo

Number of subjects included in analysis	124
Analysis specification	Pre-specified
Analysis type	superiority ^[45]
P-value	= 0.8856
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	-0.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.3
upper limit	5.45

Notes:

[45] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Change from Baseline in the Participant-Reported SMA Independence Scale (SMAIS) Total Score at Month 12

End point title	Part 2: Change from Baseline in the Participant-Reported SMA Independence Scale (SMAIS) Total Score at Month 12 ^[46]
-----------------	---

End point description:

The SMAIS was developed specifically for SMA participants in order to assess function-related independence. It contains 29 items, assessing the amount of assistance required from another individual to perform daily activities such as eating, or bathing. Each item is scored on a 0-4 scale (with an additional option to indicate that an item is non-applicable). The SMAIS total score ranging from 0-44 is obtained based on 22 items with each item on the 0-2 scale. Lower scores indicate greater dependence on another individual. The SMAIS was completed by participants aged 12 years or older and caregivers of participants aged 2-25 years. MMRM analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. . ITT population except subjects without SMAIS total score at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day-1) and Month 12

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	23		
Units: Scores on a Scale				
least squares mean (confidence interval 95%)	1.04 (-0.26 to 2.35)	-0.40 (-2.13 to 1.32)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
Comparison groups	Part 2: Risdiplam v Part 2: Placebo

Number of subjects included in analysis	66
Analysis specification	Pre-specified
Analysis type	superiority ^[47]
P-value	= 0.1778
Method	Mixed Model Repeated Measure Analysis
Parameter estimate	Least Square Mean Difference
Point estimate	1.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.68
upper limit	3.57

Notes:

[47] - The variables included in the MMRM model are: baseline total score, treatment, age group, visit, treatment-by-visit and baseline score-by-visit interaction.

Secondary: Part 2: Percentage of Participants Rated by Clinicians as No Change or Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12

End point title	Part 2: Percentage of Participants Rated by Clinicians as No Change or Improved in the Clinical Global Impression of Change (CGI-C) Scale Ratings at Month 12 ^[48]
-----------------	---

End point description:

The CGI-C is used to score a clinician's impression of a participant's change in global health. It is a single item measure of change in global health, using seven response options: "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", and "very much worse". Participants considered as "no change or improved" included responses of "no change", "very much improved", "much improved" and "minimally improved". Logistic regression analysis was performed based on efficacy hypothetical estimand, which included participants data assuming no prohibited medication intended for treatment of SMA was received and participants continued on their randomized treatment until the analysis time point at Month 12. ITT population: all randomized participants in Part 2. Missing results at Month 12 are considered as non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

At Month 12

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	60		
Units: Percentage of Participants				
number (confidence interval 95%)	85.8 (79.18 to 92.49)	83.3 (73.07 to 93.60)		

Statistical analyses

Statistical analysis title	Part 2: Risdiplam versus Placebo
----------------------------	----------------------------------

Statistical analysis description:

CGI No Change or Improved

Comparison groups	Part 2: Risdiplam v Part 2: Placebo
Number of subjects included in analysis	180
Analysis specification	Pre-specified
Analysis type	superiority ^[49]
P-value	= 0.6636
Method	Wald-test
Parameter estimate	Odds ratio (OR)
Point estimate	1.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.52
upper limit	2.83

Notes:

[49] - Logistic Regression Model. The variables included in the logistic regression are: baseline total score, treatment and age group.

Secondary: Part 2: Percentage of Participants who Experience at Least One Disease-Related Adverse Event at Month 12

End point title	Part 2: Percentage of Participants who Experience at Least One Disease-Related Adverse Event at Month 12 ^[50]
-----------------	--

End point description:

Disease-related adverse events (AEs) were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms. This basket was defined based on a group of CDC terms selected from an age and gender matched case control study comparing CDC code rates observed in participants with and without SMA using commercially available insurance claim data (CLAIMS and Market scan data). The lowest level terms included in each basket, coded using the latest version of MedDRA; Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Month 12 (Week 52; up to CCOD of 06 September 2019)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	60		
Units: Percentage of Participants				
number (confidence interval 95%)				
Narrow Basket AEs	46.7 (37.51 to 55.99)	53.3 (40.00 to 66.33)		
Broad Basket AEs	65.0 (55.76 to 73.48)	60.0 (46.54 to 72.44)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Number of disease-related adverse events per patient-years at Month 12

End point title	Part 2: Number of disease-related adverse events per patient-years at Month 12 ^[51]
-----------------	--

End point description:

Disease-related AEs were collected through the AE reporting of the study, and the disease-related AE rate was adjusted for patient years (AE rate per 100 patient-years). They were identified by applying two different types of baskets to the AE dataset: Narrow prospectively defined baskets of MedDRA lowest level terms and Broad prospectively defined basket with events selected at preferred term level from all AEs reported in ongoing clinical trials up to January 2019, i.e., prior to unblinding of Part 2 of Study BP39055.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Month 12 (Week 52; up to CCOD of 06 September 2019)

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	60		
Units: Number of Events per 100 Patient-Years				
number (confidence interval 95%)				
Narrow Basket AEs	101.51 (84.23 to 121.29)	119.77 (93.71 to 150.82)		
Broad Basket AEs	217.29 (191.63 to 245.42)	199.61 (165.50 to 238.68)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period

End point title	Part 2: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period ^[52]
-----------------	---

End point description:

An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to 12 months of the placebo-controlled period

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	60		
Units: Percentage of Participants				
number (not applicable)				
With at Least One AE	92.5	91.7		
With at Least One SAE	20.0	18.3		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Percentage of Participants with Treatment Discontinuation due to Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period

End point title	Part 2: Percentage of Participants with Treatment Discontinuation due to Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Placebo-Controlled Period ^[53]
-----------------	--

End point description:

An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to 12 months of the placebo-controlled period

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	60		
Units: Percentage of Participants				
number (not applicable)				
Due to AE	0.0	0.0		
Due to SAE	0.0	0.0		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Number of Participants Aged 6-25 Years with Suicidal Ideation Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period

End point title	Part 2: Number of Participants Aged 6-25 Years with Suicidal Ideation Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period ^[54]
-----------------	---

End point description:

The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to 12 months of the placebo-controlled period

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	42		
Units: Number of Participants				
Wish to be Dead	1	1		
Non-specific Active Suicidal Thoughts	1	1		
Ideation with Any Methods, No Intent to Act	1	1		
Ideation with Some Intent to Act, No Plan	0	1		
Ideation with Specific Plan and Intent	0	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 2: Number of Participants Aged 6-25 Years with Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period

End point title	Part 2: Number of Participants Aged 6-25 Years with Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) in the Placebo-Controlled Period ^[55]
-----------------	---

End point description:

The Columbia Suicide Severity Rating Scale (C-SSRS) is used to assess the lifetime suicidality of a participant (C-SSRS baseline) as well as any new instances of suicidality (C-SSRS since last visit). The structured interview prompts recollection of suicidal ideation, including the intensity of the ideation, behavior, and attempts with actual/potential lethality. The C-SSRS assessments results were collected for participants aged 6 years and older.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 up to 12 months of the placebo-controlled period

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only Part 2 arms were included in this end point.

End point values	Part 2: Risdiplam	Part 2: Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	42		
Units: Number of Participants				
Preparatory Acts or Behavior	0	0		
Aborted Attempt	0	0		
Interrupted Attempt	0	0		
Actual Attempt (non-fatal)	0	0		
Completed Suicide	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Median Fold Change from Baseline in Survival of Motor Neuron (SMN) Protein Levels in Blood

End point title	Median Fold Change from Baseline in Survival of Motor Neuron (SMN) Protein Levels in Blood
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1: Day -1, pre-dose of Weeks 1, 2 (≥ 12 years only), 17, 35 and 104, and at 4h post-dose of Weeks 4 and 52. Part 2: Day -1, pre-dose of Weeks 1, 17, 35 and 104, and at 4h post-dose of Weeks 4 and 52.

End point values	Part 1: All Risdiplam	Part 2: All Risdiplam		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	51	169		
Units: unitless				
median (full range (min-max))	2.91 (2.14 to 4.18)	1.96 (0.2 to 4.48)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam at Year 5

End point title	Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam at Year 5
End point description: Reported here is the maximum observed concentration throughout the observation period.	
End point type	Secondary
End point timeframe: Day 1: 1, 2, 4, 6 h postdose, Weeks 4, 8 (Part 1 only), 52, 87: pre-dose, 1, 2, 4, 6 h post-dose and Weeks 1 (Day 7), 2, 8 (Part 2 only) 17, 35, 70, 104: predose	

End point values	Part 1: All Risdiplam	Part 2: All Risdiplam		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	51	179		
Units: nanograms/milliliter (ng/mL)				
median (full range (min-max))	137 (58.2 to 242)	140 (42.7 to 313)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1 and 2: Area Under the Curve (AUC) from 0 to 24 Hours of Risdiplam at Year 5 Visit

End point title	Part 1 and 2: Area Under the Curve (AUC) from 0 to 24 Hours of Risdiplam at Year 5 Visit
End point description:	
End point type	Secondary
End point timeframe: Year 5 visit pre-dose, 1, 2, 4, 6, 24 hours post-dose	

End point values	Part 1: All Risdiplam	Part 2: All Risdiplam		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	49	160		
Units: ng*h/mL				
median (full range (min-max))	1700 (1160 to 2590)	1880 (1200 to 2890)		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam at Year 5

End point title	Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam at Year 5
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

The last predose sample collected from each participant who had at least 1400 days of risdiplam treatment duration.

End point values	Part 1: All Risdiplam	Part 2: All Risdiplam		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	49	107		
Units: ng/mL				
median (full range (min-max))	54.1 (21.3 to 108)	57.2 (4.50 to 229)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Part 1 and Part 2: Up to approximately 5 years

Adverse event reporting additional description:

The safety population included all participants who received at least one dose of study medication (risdiplam or placebo) whether prematurely withdrawn or not.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

Reporting groups

Reporting group title	Part 1 Group A: Adolescents/Adults (3 mg Risdiplam)
-----------------------	---

Reporting group description:

Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 1 Group A: OLE
-----------------------	---------------------

Reporting group description:

Once the placebo-controlled period was completed and Part 2 dose was selected, adolescents and adults switched to Part 2 dose and were treated in an open-label extension (OLE) phase.

Reporting group title	Part 1 Group B: Children (Placebo-Control Period Pooled)
-----------------------	--

Reporting group description:

Children aged 2-11 years received placebo matching to risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 1 Group B: Children (0.25 mg/kg Risdiplam)
-----------------------	---

Reporting group description:

Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 1 Group B: Children (0.15 mg/kg Risdiplam)
-----------------------	---

Reporting group description:

Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 1 Group B: Children (0.05 mg/kg Risdiplam)
-----------------------	---

Reporting group description:

Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 1 Group A: Adolescents/Adults (5 mg Risdiplam)
-----------------------	---

Reporting group description:

Adolescent and adult participants aged 12-25 years received risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 1 Group A: Adolescents/Adults (Placebo-Control Pooled)
-----------------------	---

Reporting group description:

Adolescent and adult participants aged 12-25 years received placebo matching to risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 1 Group B: Children (0.02 mg/kg Risdiplam)
-----------------------	---

Reporting group description:

Children aged 2-11 years received risdiplam for at least 12 weeks during the placebo-controlled period.

Reporting group title	Part 2 OLT: Risdiplam/Risdiplam
-----------------------	---------------------------------

Reporting group description:

Once the Part 2 placebo-controlled period was completed participants received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for another 12 months (Month 12-24) in the open-label treatment (OLT) phase.

Reporting group title	Part 2 Placebo-Controlled: Placebo
-----------------------	------------------------------------

Reporting group description:

Participants aged 2-25 years received placebo matching to risdiplam for 12 months during the placebo-

controlled period.

Reporting group title	Part 2 Placebo-Controlled: Risdiplam
-----------------------	--------------------------------------

Reporting group description:

Participants aged 2-25 years received risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months during the placebo-controlled period..

Reporting group title	Part 1 Group B: OLE
-----------------------	---------------------

Reporting group description:

Once the placebo-controlled period was completed and Part 2 dose was selected, children switched to Part 2 dose and were treated in an open-label extension (OLE) phase.

Reporting group title	Part 2 OLT: Placebo/Risdiplam
-----------------------	-------------------------------

Reporting group description:

Once the Part 2 placebo-controlled period was completed participants switched to risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg for 12 months (Month 12-24) in the open-label treatment (OLT) phase.

Reporting group title	Part 2 OLE: Risdiplam
-----------------------	-----------------------

Reporting group description:

Once the Part 2 OLT period ended participants entered the open-label extension period and continued to receive risdiplam at the dose of 5 mg once daily for participants with a body weight (BW) ≥ 20 kg or 0.25 mg/kg for participants with a BW < 20 kg.

Serious adverse events	Part 1 Group A: Adolescents/Adults (3 mg Risdiplam)	Part 1 Group A: OLE	Part 1 Group B: Children (Placebo- Control Period Pooled)
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 10 (10.00%)	5 / 20 (25.00%)	1 / 10 (10.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial vein thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Ill-defined disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis aspiration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Affective disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encopresis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device breakage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Oxygen saturation decreased subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Near drowning			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Humerus fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Spontaneous haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Oesophagitis			

subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malpositioned teeth			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hypertransaminasaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 1 Group B: Children (0.25 mg/kg Risdiplam)	Part 1 Group B: Children (0.15 mg/kg Risdiplam)	Part 1 Group B: Children (0.05 mg/kg Risdiplam)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from			

adverse events			
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Ill-defined disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic respiratory failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis aspiration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Affective disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encopresis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device breakage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Oxygen saturation decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Near drowning			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain contusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Febrile convulsion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Spontaneous haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Oesophagitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Constipation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malpositioned teeth			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hypertransaminasaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia mycoplasmal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 1 Group A: Adolescents/Adults (5 mg Risdiplam)	Part 1 Group A: Adolescents/Adults (Placebo-Control Pooled)	Part 1 Group B: Children (0.02 mg/kg Risdiplam)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial vein thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Ill-defined disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis aspiration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Affective disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encopresis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device breakage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Oxygen saturation decreased subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Near drowning			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Humerus fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Spontaneous haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Oesophagitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malpositioned teeth			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hypertransaminasaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Upper respiratory tract infection subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 2 OLT: Risdiplam/Risdiplam	Part 2 Placebo- Controlled: Placebo	Part 2 Placebo- Controlled: Risdiplam
Total subjects affected by serious adverse events			
subjects affected / exposed	25 / 117 (21.37%)	11 / 60 (18.33%)	24 / 120 (20.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from			

adverse events			
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial vein thrombosis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Ill-defined disorder			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device pain			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	2 / 120 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic respiratory failure			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			

subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis aspiration			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			

subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Affective disorder			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encopresis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device breakage			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Oxygen saturation decreased			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Near drowning			

subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain contusion			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Febrile convulsion			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Spontaneous haematoma			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Oesophagitis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Constipation			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	2 / 117 (1.71%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malpositioned teeth			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hypertransaminasaemia			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 117 (0.85%)	1 / 60 (1.67%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 117 (0.00%)	2 / 60 (3.33%)	2 / 120 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia mycoplasmal			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	2 / 120 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	8 / 117 (6.84%)	2 / 60 (3.33%)	10 / 120 (8.33%)
occurrences causally related to treatment / all	0 / 10	0 / 2	0 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	2 / 120 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective thrombosis			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			

subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 117 (0.85%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			

subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 1 Group B: OLE	Part 2 OLT: Placebo/Risdiplam	Part 2 OLE: Risdiplam
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 31 (29.03%)	4 / 59 (6.78%)	34 / 175 (19.43%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial vein thrombosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Ill-defined disorder			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Medical device pain			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	2 / 175 (1.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic respiratory failure			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive sleep apnoea syndrome			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis aspiration			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Affective disorder			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encopresis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device breakage			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Oxygen saturation decreased subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	2 / 31 (6.45%)	0 / 59 (0.00%)	3 / 175 (1.71%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Near drowning			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain contusion			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Musculoskeletal procedural complication			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Humerus fracture			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Cryptorchism			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Spontaneous haematoma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Oesophagitis			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental caries			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malpositioned teeth			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hypertransaminasaemia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	2 / 175 (1.14%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia mycoplasmal			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	8 / 175 (4.57%)
occurrences causally related to treatment / all	0 / 1	0 / 0	3 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Upper respiratory tract infection subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	2 / 175 (1.14%)
occurrences causally related to treatment / all	0 / 1	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	2 / 175 (1.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			

subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Helicobacter infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective thrombosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	2 / 175 (1.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part 1 Group A: Adolescents/Adults (3 mg Risdiplam)	Part 1 Group A: OLE	Part 1 Group B: Children (Placebo- Control Period Pooled)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 10 (90.00%)	17 / 20 (85.00%)	9 / 10 (90.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	0 / 10 (0.00%)
occurrences (all)	1	3	0
Catheter site extravasation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 10 (20.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Granuloma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hyperpyrexia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	1 / 10 (10.00%)
occurrences (all)	1	1	2
Pyrexia			
subjects affected / exposed	2 / 10 (20.00%)	9 / 20 (45.00%)	3 / 10 (30.00%)
occurrences (all)	4	19	5
Hyperthermia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 20 (10.00%) 3	0 / 10 (0.00%) 0
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all) Dysmenorrhoea subjects affected / exposed occurrences (all) Amenorrhoea subjects affected / exposed occurrences (all) Premenstrual pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0 1 / 10 (10.00%) 1 1 / 10 (10.00%) 1 0 / 10 (0.00%) 0	1 / 20 (5.00%) 1 4 / 20 (20.00%) 27 0 / 20 (0.00%) 0 1 / 20 (5.00%) 1	0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Lower respiratory tract inflammation subjects affected / exposed occurrences (all) Nasal congestion subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 2 / 10 (20.00%) 2	4 / 20 (20.00%) 5 1 / 20 (5.00%) 1 1 / 20 (5.00%) 1 0 / 20 (0.00%) 0 3 / 20 (15.00%) 6	2 / 10 (20.00%) 4 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 1 / 10 (10.00%) 2

Pleurisy			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Respiratory tract inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	0 / 10 (0.00%)
occurrences (all)	1	6	0
Rhinorrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 10 (0.00%)	3 / 20 (15.00%)	2 / 10 (20.00%)
occurrences (all)	0	5	2
Asthma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Initial insomnia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Investigations			
Gastric pH decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme increased			

subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Arthropod bite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Face injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Femur fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Foot fracture			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Ligament sprain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Tooth dislocation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Sinus tachycardia			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	0 / 20 (0.00%) 0	0 / 10 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 3	3 / 20 (15.00%) 60	0 / 10 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	0 / 10 (0.00%) 0
Blood and lymphatic system disorders Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 20 (0.00%) 0	0 / 10 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
Motion sickness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	1 / 10 (10.00%) 2
Eye disorders Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 20 (0.00%) 0	1 / 10 (10.00%) 1
Ocular hyperaemia			

subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Eczema eyelids			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Corneal infiltrates			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Retinal dystrophy			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Vision blurred			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 10 (10.00%)	2 / 20 (10.00%)	1 / 10 (10.00%)
occurrences (all)	1	2	1
Abdominal pain upper			
subjects affected / exposed	0 / 10 (0.00%)	3 / 20 (15.00%)	1 / 10 (10.00%)
occurrences (all)	0	4	1
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Aphthous ulcer			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Faecaloma			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	2	0

Lip pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	1 / 10 (10.00%)
occurrences (all)	0	3	1
Swollen tongue			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Oral mucosal erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tongue oedema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	4 / 20 (20.00%)	1 / 10 (10.00%)
occurrences (all)	0	6	1
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	4	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Alopecia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Hyperkeratosis			

subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Eczema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	2 / 10 (20.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Dermatitis diaper			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Palmar erythema			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	3	0	0
Rash			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Rash papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Skin induration			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Urinary tract pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 10 (10.00%)
occurrences (all)	0	1	2
Myalgia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	4 / 20 (20.00%)	0 / 10 (0.00%)
occurrences (all)	0	14	0
Neck pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	13	0
Osteoporosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
COVID-19			
subjects affected / exposed	0 / 10 (0.00%)	3 / 20 (15.00%)	0 / 10 (0.00%)
occurrences (all)	0	3	0
Cystitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Ear infection			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	1 / 10 (10.00%)
occurrences (all)	0	2	1
Ear infection fungal			

subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	4 / 20 (20.00%)	1 / 10 (10.00%)
occurrences (all)	0	7	1
Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Laryngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 10 (10.00%)	4 / 20 (20.00%)	0 / 10 (0.00%)
occurrences (all)	1	12	0
Groin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Laryngitis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Pharyngitis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	1	3	0
Nasopharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	3 / 20 (15.00%)	1 / 10 (10.00%)
occurrences (all)	0	7	1
Scarlet fever			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rhinitis			

subjects affected / exposed	1 / 10 (10.00%)	1 / 20 (5.00%)	1 / 10 (10.00%)
occurrences (all)	1	1	1
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	3 / 20 (15.00%)	0 / 10 (0.00%)
occurrences (all)	0	10	0
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	2 / 20 (10.00%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Viral infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Varicella			
subjects affected / exposed	0 / 10 (0.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Iron deficiency			
subjects affected / exposed	0 / 10 (0.00%)	1 / 20 (5.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Decreased appetite			
subjects affected / exposed	1 / 10 (10.00%)	0 / 20 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0

Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 20 (5.00%) 1	0 / 10 (0.00%) 0
--	---------------------	---------------------	---------------------

Non-serious adverse events	Part 1 Group B: Children (0.25 mg/kg Risdiplam)	Part 1 Group B: Children (0.15 mg/kg Risdiplam)	Part 1 Group B: Children (0.05 mg/kg Risdiplam)
Total subjects affected by non-serious adverse events subjects affected / exposed	6 / 7 (85.71%)	18 / 21 (85.71%)	12 / 14 (85.71%)
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Catheter site extravasation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1
Fatigue subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 21 (4.76%) 1	0 / 14 (0.00%) 0
Granuloma subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1
Hyperpyrexia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	4 / 21 (19.05%) 5	3 / 14 (21.43%) 4
Hyperthermia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0

Oedema subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 2	1 / 14 (7.14%) 2
Pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Amenorrhoea subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Premenstrual pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 2	3 / 21 (14.29%) 4	2 / 14 (14.29%) 2
Dyspnoea subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Lower respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0

Oropharyngeal pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	2	2
Pleurisy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory tract inflammation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	1 / 7 (14.29%)	1 / 21 (4.76%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 7 (14.29%)	1 / 21 (4.76%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Asthma			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Epistaxis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Initial insomnia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Investigations			

Gastric pH decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Hepatic enzyme increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1
Arthropod bite subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	2 / 21 (9.52%) 3	2 / 14 (14.29%) 3
Face injury subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Femur fracture subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1
Foot fracture subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Ligament sprain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 21 (4.76%) 1	0 / 14 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Tooth dislocation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1
Cardiac disorders			

Palpitations			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 7 (14.29%)	2 / 21 (9.52%)	1 / 14 (7.14%)
occurrences (all)	2	20	18
Dizziness			
subjects affected / exposed	1 / 7 (14.29%)	1 / 21 (4.76%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Eye disorders			

Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Eczema eyelids subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1
Corneal infiltrates subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Retinal dystrophy subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Vision blurred subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 21 (4.76%) 1	1 / 14 (7.14%) 1
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 2	1 / 21 (4.76%) 2	0 / 14 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Aphthous ulcer subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Faecaloma subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 21 (0.00%) 0	0 / 14 (0.00%) 0
Diarrhoea			

subjects affected / exposed	1 / 7 (14.29%)	1 / 21 (4.76%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lip pruritus			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Nausea			
subjects affected / exposed	1 / 7 (14.29%)	2 / 21 (9.52%)	1 / 14 (7.14%)
occurrences (all)	1	2	1
Swollen tongue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oral mucosal erythema			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Tongue oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 7 (14.29%)	5 / 21 (23.81%)	4 / 14 (28.57%)
occurrences (all)	1	7	6
Toothache			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1

Dermatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dermatitis diaper			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Palmar erythema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Rash			
subjects affected / exposed	1 / 7 (14.29%)	3 / 21 (14.29%)	2 / 14 (14.29%)
occurrences (all)	1	3	2
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Erythema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin induration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Renal and urinary disorders			
Urinary tract pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Osteoporosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Ear infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Ear infection fungal			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	2	2
Gastroenteritis			
subjects affected / exposed	1 / 7 (14.29%)	1 / 21 (4.76%)	0 / 14 (0.00%)
occurrences (all)	2	2	0
Gastroenteritis viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Influenza			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Groin infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Gastrointestinal infection			
subjects affected / exposed	1 / 7 (14.29%)	1 / 21 (4.76%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Laryngitis viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	2 / 21 (9.52%)	2 / 14 (14.29%)
occurrences (all)	0	2	2
Nasopharyngitis			
subjects affected / exposed	1 / 7 (14.29%)	2 / 21 (9.52%)	1 / 14 (7.14%)
occurrences (all)	1	2	1

Scarlet fever			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	2 / 7 (28.57%)	3 / 21 (14.29%)	1 / 14 (7.14%)
occurrences (all)	2	3	1
Skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 21 (4.76%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Tooth abscess			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 7 (28.57%)	4 / 21 (19.05%)	2 / 14 (14.29%)
occurrences (all)	3	5	2
Urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Varicella			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Iron deficiency			

subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 21 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 1 Group A: Adolescents/Adults (5 mg Risdiplam)	Part 1 Group A: Adolescents/Adults (Placebo-Control Pooled)	Part 1 Group B: Children (0.02 mg/kg Risdiplam)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 10 (80.00%)	4 / 6 (66.67%)	6 / 7 (85.71%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Catheter site extravasation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Granuloma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperpyrexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	2 / 7 (28.57%)
occurrences (all)	2	0	2

Hyperthermia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Oedema subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Dysmenorrhoea subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 7	1 / 6 (16.67%) 3	0 / 7 (0.00%) 0
Amenorrhoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Premenstrual pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Dyspnoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0

Lower respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 4	1 / 6 (16.67%) 1	1 / 7 (14.29%) 2
Pleurisy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Asthma subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Epistaxis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Productive cough subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Psychiatric disorders Depression			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Initial insomnia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Investigations			
Gastric pH decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Hepatic enzyme increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Face injury subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Femur fracture subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Foot fracture subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Ligament sprain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Limb injury			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Tooth dislocation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders			
Palpitations subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 3	0 / 6 (0.00%) 0	1 / 7 (14.29%) 18
Dizziness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders			
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Vertigo			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Motion sickness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Eye disorders			
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Eczema eyelids subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Corneal infiltrates subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Retinal dystrophy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Vision blurred subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Aphthous ulcer			

subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Faecaloma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lip pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Swollen tongue			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oral mucosal erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tongue oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	2 / 7 (28.57%)
occurrences (all)	1	0	4
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Alopecia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hyperkeratosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 10 (0.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Dermatitis diaper			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Palmar erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 10 (0.00%)	1 / 6 (16.67%)	1 / 7 (14.29%)
occurrences (all)	0	3	1
Rash			
subjects affected / exposed	1 / 10 (10.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Erythema subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Skin induration subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders Urinary tract pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Osteoporosis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Infections and infestations Conjunctivitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0

COVID-19			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear infection fungal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	1 / 10 (10.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Groin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Laryngitis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Pharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	2
Nasopharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Scarlet fever			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	2 / 10 (20.00%)	1 / 6 (16.67%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
Skin infection			
subjects affected / exposed	1 / 10 (10.00%)	1 / 6 (16.67%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Tonsillitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 6 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Varicella subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Metabolism and nutrition disorders			
Iron deficiency subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0

Non-serious adverse events	Part 2 OLT: Risdiplam/Risdiplam	Part 2 Placebo- Controlled: Placebo	Part 2 Placebo- Controlled: Risdiplam
Total subjects affected by non-serious adverse events subjects affected / exposed	88 / 117 (75.21%)	50 / 60 (83.33%)	101 / 120 (84.17%)
Vascular disorders			
Hypertension subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Catheter site extravasation subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	1 / 60 (1.67%) 1	1 / 120 (0.83%) 1
Granuloma subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Hyperpyrexia			

subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	1 / 120 (0.83%) 1
Pyrexia subjects affected / exposed occurrences (all)	15 / 117 (12.82%) 22	10 / 60 (16.67%) 20	25 / 120 (20.83%) 41
Hyperthermia subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	3 / 117 (2.56%) 3	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Oedema subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	1 / 60 (1.67%) 1	1 / 120 (0.83%) 1
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	1 / 60 (1.67%) 1	0 / 120 (0.00%) 0
Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	0 / 60 (0.00%) 0	2 / 120 (1.67%) 2
Amenorrhoea subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Premenstrual pain subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	12 / 117 (10.26%)	12 / 60 (20.00%)	17 / 120 (14.17%)
occurrences (all)	16	19	27
Dyspnoea			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	0	0	1
Lower respiratory tract inflammation			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	1 / 117 (0.85%)	1 / 60 (1.67%)	1 / 120 (0.83%)
occurrences (all)	1	1	1
Oropharyngeal pain			
subjects affected / exposed	4 / 117 (3.42%)	7 / 60 (11.67%)	6 / 120 (5.00%)
occurrences (all)	4	8	6
Pleurisy			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Respiratory tract inflammation			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	1 / 117 (0.85%)	2 / 60 (3.33%)	1 / 120 (0.83%)
occurrences (all)	1	3	1
Rhinorrhoea			
subjects affected / exposed	3 / 117 (2.56%)	3 / 60 (5.00%)	6 / 120 (5.00%)
occurrences (all)	4	3	6
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences (all)	0	1	0
Asthma			
subjects affected / exposed	1 / 117 (0.85%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences (all)	1	1	0
Epistaxis			
subjects affected / exposed	1 / 117 (0.85%)	3 / 60 (5.00%)	3 / 120 (2.50%)
occurrences (all)	1	5	4

Productive cough subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	3 / 60 (5.00%) 3	0 / 120 (0.00%) 0
Psychiatric disorders			
Depression subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Initial insomnia subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Investigations			
Gastric pH decreased subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Hepatic enzyme increased subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	2 / 117 (1.71%) 2	0 / 60 (0.00%) 0	5 / 120 (4.17%) 5
Arthropod bite subjects affected / exposed occurrences (all)	2 / 117 (1.71%) 2	1 / 60 (1.67%) 2	3 / 120 (2.50%) 3
Face injury subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Femur fracture subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	1 / 120 (0.83%) 1
Fall subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	2 / 120 (1.67%) 4
Foot fracture subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0

Ligament sprain subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	2 / 120 (1.67%) 2
Limb injury subjects affected / exposed occurrences (all)	3 / 117 (2.56%) 3	0 / 60 (0.00%) 0	1 / 120 (0.83%) 1
Tooth dislocation subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Cardiac disorders			
Palpitations subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	1 / 120 (0.83%) 2
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	12 / 117 (10.26%) 76	10 / 60 (16.67%) 23	24 / 120 (20.00%) 88
Dizziness subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	2 / 60 (3.33%) 2	0 / 120 (0.00%) 0
Blood and lymphatic system disorders			
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	1 / 120 (0.83%) 1
Neutropenia subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	1 / 60 (1.67%) 1	1 / 120 (0.83%) 1
Ear and labyrinth disorders			

Ear pain			
subjects affected / exposed	5 / 117 (4.27%)	2 / 60 (3.33%)	3 / 120 (2.50%)
occurrences (all)	5	2	4
Vertigo			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Motion sickness			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	2 / 120 (1.67%)
occurrences (all)	0	0	2
Eye disorders			
Conjunctival hyperaemia			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	1	0	1
Eczema eyelids			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Corneal infiltrates			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Retinal dystrophy			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	7 / 117 (5.98%)	5 / 60 (8.33%)	8 / 120 (6.67%)
occurrences (all)	10	6	10
Abdominal pain upper			
subjects affected / exposed	1 / 117 (0.85%)	2 / 60 (3.33%)	7 / 120 (5.83%)
occurrences (all)	1	3	7
Constipation			

subjects affected / exposed	4 / 117 (3.42%)	3 / 60 (5.00%)	9 / 120 (7.50%)
occurrences (all)	4	3	10
Aphthous ulcer			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	3 / 120 (2.50%)
occurrences (all)	1	0	4
Faecaloma			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	10 / 117 (8.55%)	5 / 60 (8.33%)	21 / 120 (17.50%)
occurrences (all)	12	5	27
Gastrointestinal disorder			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Lip pruritus			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	4 / 117 (3.42%)	3 / 60 (5.00%)	11 / 120 (9.17%)
occurrences (all)	5	4	13
Swollen tongue			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Oral mucosal erythema			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences (all)	0	1	0
Tongue oedema			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	15 / 117 (12.82%)	14 / 60 (23.33%)	17 / 120 (14.17%)
occurrences (all)	31	22	35
Toothache			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			

Acne			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	3 / 120 (2.50%)
occurrences (all)	1	0	3
Alopecia			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	1	0	0
Blister			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	1	0	1
Dermatitis			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	1	0	0
Hyperkeratosis			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	3 / 117 (2.56%)	1 / 60 (1.67%)	5 / 120 (4.17%)
occurrences (all)	3	1	5
Dry skin			
subjects affected / exposed	2 / 117 (1.71%)	0 / 60 (0.00%)	2 / 120 (1.67%)
occurrences (all)	2	0	2
Dermatitis diaper			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Palmar erythema			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	2 / 117 (1.71%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	2	0	1
Rash			
subjects affected / exposed	6 / 117 (5.13%)	1 / 60 (1.67%)	9 / 120 (7.50%)
occurrences (all)	6	1	11
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	1	0	2

Rash papular subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	1 / 120 (0.83%) 1
Erythema subjects affected / exposed occurrences (all)	2 / 117 (1.71%) 2	0 / 60 (0.00%) 0	3 / 120 (2.50%) 4
Skin induration subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Renal and urinary disorders Urinary tract pain subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	3 / 117 (2.56%) 3	0 / 60 (0.00%) 0	6 / 120 (5.00%) 9
Myalgia subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	3 / 120 (2.50%) 3
Back pain subjects affected / exposed occurrences (all)	3 / 117 (2.56%) 3	2 / 60 (3.33%) 4	3 / 120 (2.50%) 4
Neck pain subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	0 / 60 (0.00%) 0	1 / 120 (0.83%) 1
Osteoporosis subjects affected / exposed occurrences (all)	0 / 117 (0.00%) 0	0 / 60 (0.00%) 0	0 / 120 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	2 / 117 (1.71%) 2	1 / 60 (1.67%) 3	4 / 120 (3.33%) 4
Infections and infestations Conjunctivitis subjects affected / exposed occurrences (all)	1 / 117 (0.85%) 1	3 / 60 (5.00%) 3	4 / 120 (3.33%) 6

Bronchitis			
subjects affected / exposed	6 / 117 (5.13%)	10 / 60 (16.67%)	7 / 120 (5.83%)
occurrences (all)	7	12	9
COVID-19			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	3 / 120 (2.50%)
occurrences (all)	2	0	5
Ear infection			
subjects affected / exposed	3 / 117 (2.56%)	2 / 60 (3.33%)	2 / 120 (1.67%)
occurrences (all)	3	2	2
Ear infection fungal			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	9 / 117 (7.69%)	5 / 60 (8.33%)	7 / 120 (5.83%)
occurrences (all)	9	6	10
Gastroenteritis viral			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	4 / 120 (3.33%)
occurrences (all)	0	1	4
Laryngitis			
subjects affected / exposed	0 / 117 (0.00%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences (all)	0	1	0
Influenza			
subjects affected / exposed	3 / 117 (2.56%)	3 / 60 (5.00%)	3 / 120 (2.50%)
occurrences (all)	3	4	3
Groin infection			
subjects affected / exposed	1 / 117 (0.85%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences (all)	1	1	0
Gastrointestinal infection			
subjects affected / exposed	2 / 117 (1.71%)	1 / 60 (1.67%)	0 / 120 (0.00%)
occurrences (all)	2	1	0
Laryngitis viral			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0

Pneumonia			
subjects affected / exposed	2 / 117 (1.71%)	3 / 60 (5.00%)	5 / 120 (4.17%)
occurrences (all)	2	3	6
Pharyngitis			
subjects affected / exposed	6 / 117 (5.13%)	3 / 60 (5.00%)	6 / 120 (5.00%)
occurrences (all)	6	3	8
Nasopharyngitis			
subjects affected / exposed	26 / 117 (22.22%)	15 / 60 (25.00%)	31 / 120 (25.83%)
occurrences (all)	34	21	54
Scarlet fever			
subjects affected / exposed	1 / 117 (0.85%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	1 / 117 (0.85%)	3 / 60 (5.00%)	5 / 120 (4.17%)
occurrences (all)	1	4	10
Respiratory tract infection			
subjects affected / exposed	7 / 117 (5.98%)	6 / 60 (10.00%)	8 / 120 (6.67%)
occurrences (all)	8	9	10
Skin infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	1 / 117 (0.85%)	2 / 60 (3.33%)	3 / 120 (2.50%)
occurrences (all)	1	4	4
Tooth abscess			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	18 / 117 (15.38%)	18 / 60 (30.00%)	38 / 120 (31.67%)
occurrences (all)	24	27	54
Urinary tract infection			
subjects affected / exposed	2 / 117 (1.71%)	0 / 60 (0.00%)	6 / 120 (5.00%)
occurrences (all)	3	0	7
Viral infection			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	1 / 120 (0.83%)
occurrences (all)	0	0	1

Sinusitis			
subjects affected / exposed	2 / 117 (1.71%)	2 / 60 (3.33%)	4 / 120 (3.33%)
occurrences (all)	2	4	5
Varicella			
subjects affected / exposed	0 / 117 (0.00%)	3 / 60 (5.00%)	3 / 120 (2.50%)
occurrences (all)	0	3	3
Metabolism and nutrition disorders			
Iron deficiency			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	2 / 117 (1.71%)	0 / 60 (0.00%)	2 / 120 (1.67%)
occurrences (all)	2	0	2
Vitamin D deficiency			
subjects affected / exposed	0 / 117 (0.00%)	0 / 60 (0.00%)	0 / 120 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 1 Group B: OLE	Part 2 OLT: Placebo/Risdiplam	Part 2 OLE: Risdiplam
Total subjects affected by non-serious adverse events			
subjects affected / exposed	28 / 31 (90.32%)	40 / 59 (67.80%)	140 / 175 (80.00%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Catheter site extravasation			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	3 / 31 (9.68%)	0 / 59 (0.00%)	4 / 175 (2.29%)
occurrences (all)	5	0	4
Granuloma			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Hyperpyrexia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	18 / 31 (58.06%)	6 / 59 (10.17%)	30 / 175 (17.14%)
occurrences (all)	52	7	38
Hyperthermia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	6 / 175 (3.43%)
occurrences (all)	0	0	6
Oedema			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	2 / 175 (1.14%)
occurrences (all)	0	0	2
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	2 / 31 (6.45%)	0 / 59 (0.00%)	4 / 175 (2.29%)
occurrences (all)	2	0	4
Reproductive system and breast disorders			
Heavy menstrual bleeding			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	1
Dysmenorrhoea			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	1 / 175 (0.57%)
occurrences (all)	0	2	1
Amenorrhoea			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	1
Premenstrual pain			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	11 / 31 (35.48%)	5 / 59 (8.47%)	14 / 175 (8.00%)
occurrences (all)	31	7	19
Dyspnoea			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	2
Lower respiratory tract inflammation			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	2 / 31 (6.45%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	2	0	1
Oropharyngeal pain			
subjects affected / exposed	6 / 31 (19.35%)	1 / 59 (1.69%)	11 / 175 (6.29%)
occurrences (all)	8	1	16
Pleurisy			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Respiratory tract inflammation			
subjects affected / exposed	3 / 31 (9.68%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	4	0	0
Rhinitis allergic			
subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	3 / 175 (1.71%)
occurrences (all)	1	1	3
Rhinorrhoea			
subjects affected / exposed	3 / 31 (9.68%)	1 / 59 (1.69%)	10 / 175 (5.71%)
occurrences (all)	7	1	12
Upper respiratory tract inflammation			
subjects affected / exposed	4 / 31 (12.90%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	6	0	0
Asthma			

subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	2
Epistaxis			
subjects affected / exposed	1 / 31 (3.23%)	3 / 59 (5.08%)	1 / 175 (0.57%)
occurrences (all)	2	4	1
Productive cough			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	1
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	3 / 175 (1.71%)
occurrences (all)	0	0	3
Initial insomnia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Investigations			
Gastric pH decreased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	1 / 175 (0.57%)
occurrences (all)	1	1	1
Arthropod bite			
subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	2 / 175 (1.14%)
occurrences (all)	1	1	2
Face injury			
subjects affected / exposed	2 / 31 (6.45%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	2	0	0
Femur fracture			
subjects affected / exposed	3 / 31 (9.68%)	0 / 59 (0.00%)	3 / 175 (1.71%)
occurrences (all)	3	0	3
Fall			

subjects affected / exposed	3 / 31 (9.68%)	0 / 59 (0.00%)	4 / 175 (2.29%)
occurrences (all)	4	0	4
Foot fracture			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	1 / 175 (0.57%)
occurrences (all)	2	1	1
Limb injury			
subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	0 / 175 (0.00%)
occurrences (all)	2	1	0
Tooth dislocation			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	1 / 175 (0.57%)
occurrences (all)	0	1	1
Sinus tachycardia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	2 / 175 (1.14%)
occurrences (all)	2	1	2
Nervous system disorders			
Headache			
subjects affected / exposed	6 / 31 (19.35%)	11 / 59 (18.64%)	20 / 175 (11.43%)
occurrences (all)	47	32	84
Dizziness			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	7 / 175 (4.00%)
occurrences (all)	0	0	7
Blood and lymphatic system disorders			

Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 59 (1.69%) 1	0 / 175 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	2 / 175 (1.14%) 2
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	4 / 31 (12.90%) 5	2 / 59 (3.39%) 2	3 / 175 (1.71%) 4
Vertigo subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Motion sickness subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 59 (1.69%) 1	0 / 175 (0.00%) 0
Eye disorders			
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 59 (0.00%) 0	2 / 175 (1.14%) 2
Eczema eyelids subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Corneal infiltrates subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Retinal dystrophy subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Vision blurred subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	4 / 31 (12.90%)	4 / 59 (6.78%)	7 / 175 (4.00%)
occurrences (all)	6	5	15
Abdominal pain upper			
subjects affected / exposed	3 / 31 (9.68%)	1 / 59 (1.69%)	9 / 175 (5.14%)
occurrences (all)	5	1	10
Constipation			
subjects affected / exposed	4 / 31 (12.90%)	2 / 59 (3.39%)	8 / 175 (4.57%)
occurrences (all)	12	4	9
Aphthous ulcer			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	2
Faecaloma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	1 / 175 (0.57%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	3 / 31 (9.68%)	6 / 59 (10.17%)	17 / 175 (9.71%)
occurrences (all)	14	8	26
Gastrointestinal disorder			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Lip pruritus			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	3 / 31 (9.68%)	3 / 59 (5.08%)	8 / 175 (4.57%)
occurrences (all)	4	6	10
Swollen tongue			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Oral mucosal erythema			
subjects affected / exposed	2 / 31 (6.45%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	2	0	0
Tongue oedema			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0

Vomiting			
subjects affected / exposed	10 / 31 (32.26%)	9 / 59 (15.25%)	20 / 175 (11.43%)
occurrences (all)	27	13	43
Toothache			
subjects affected / exposed	0 / 31 (0.00%)	2 / 59 (3.39%)	1 / 175 (0.57%)
occurrences (all)	0	2	1
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	5 / 175 (2.86%)
occurrences (all)	0	1	6
Alopecia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	2 / 175 (1.14%)
occurrences (all)	0	0	2
Blister			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	2 / 175 (1.14%)
occurrences (all)	0	0	5
Dermatitis			
subjects affected / exposed	0 / 31 (0.00%)	1 / 59 (1.69%)	2 / 175 (1.14%)
occurrences (all)	0	1	2
Hyperkeratosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	3 / 31 (9.68%)	1 / 59 (1.69%)	5 / 175 (2.86%)
occurrences (all)	3	1	6
Dry skin			
subjects affected / exposed	1 / 31 (3.23%)	1 / 59 (1.69%)	1 / 175 (0.57%)
occurrences (all)	1	1	1
Dermatitis diaper			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Palmar erythema			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	1	0	0
Pruritus			

subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Rash			
subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	0 / 59 (0.00%) 0	7 / 175 (4.00%) 10
Seborrhoeic dermatitis			
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	2 / 175 (1.14%) 2
Rash papular			
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Erythema			
subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 5	0 / 59 (0.00%) 0	1 / 175 (0.57%) 1
Skin induration			
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Renal and urinary disorders			
Urinary tract pain			
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed occurrences (all)	5 / 31 (16.13%) 6	2 / 59 (3.39%) 2	13 / 175 (7.43%) 21
Myalgia			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	1 / 59 (1.69%) 1	3 / 175 (1.71%) 3
Back pain			
subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 3	1 / 59 (1.69%) 1	11 / 175 (6.29%) 13
Neck pain			
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 59 (0.00%) 0	1 / 175 (0.57%) 1
Osteoporosis			

subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	0 / 59 (0.00%) 0	2 / 175 (1.14%) 2
Pain in extremity subjects affected / exposed occurrences (all)	4 / 31 (12.90%) 6	3 / 59 (5.08%) 3	10 / 175 (5.71%) 12
Infections and infestations			
Conjunctivitis subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	2 / 59 (3.39%) 3	0 / 175 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	7 / 31 (22.58%) 15	4 / 59 (6.78%) 4	9 / 175 (5.14%) 11
COVID-19 subjects affected / exposed occurrences (all)	9 / 31 (29.03%) 12	1 / 59 (1.69%) 1	55 / 175 (31.43%) 60
Cystitis subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	1 / 59 (1.69%) 1	1 / 175 (0.57%) 3
Ear infection subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	1 / 59 (1.69%) 1	3 / 175 (1.71%) 3
Ear infection fungal subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	9 / 31 (29.03%) 11	5 / 59 (8.47%) 7	12 / 175 (6.86%) 18
Gastroenteritis viral subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	3 / 175 (1.71%) 5
Laryngitis subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	1 / 175 (0.57%) 1
Influenza subjects affected / exposed occurrences (all)	6 / 31 (19.35%) 8	2 / 59 (3.39%) 2	8 / 175 (4.57%) 8

Groin infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	3 / 175 (1.71%)
occurrences (all)	0	0	3
Laryngitis viral			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	12 / 175 (6.86%)
occurrences (all)	0	0	16
Pharyngitis			
subjects affected / exposed	4 / 31 (12.90%)	4 / 59 (6.78%)	7 / 175 (4.00%)
occurrences (all)	4	4	7
Nasopharyngitis			
subjects affected / exposed	12 / 31 (38.71%)	6 / 59 (10.17%)	34 / 175 (19.43%)
occurrences (all)	23	7	48
Scarlet fever			
subjects affected / exposed	2 / 31 (6.45%)	1 / 59 (1.69%)	0 / 175 (0.00%)
occurrences (all)	2	1	0
Rhinitis			
subjects affected / exposed	3 / 31 (9.68%)	3 / 59 (5.08%)	7 / 175 (4.00%)
occurrences (all)	3	3	7
Respiratory tract infection			
subjects affected / exposed	2 / 31 (6.45%)	1 / 59 (1.69%)	5 / 175 (2.86%)
occurrences (all)	3	1	5
Skin infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 59 (0.00%)	2 / 175 (1.14%)
occurrences (all)	0	0	2
Tonsillitis			
subjects affected / exposed	3 / 31 (9.68%)	2 / 59 (3.39%)	5 / 175 (2.86%)
occurrences (all)	4	2	10
Tooth abscess			
subjects affected / exposed	1 / 31 (3.23%)	0 / 59 (0.00%)	0 / 175 (0.00%)
occurrences (all)	1	0	0

Upper respiratory tract infection subjects affected / exposed occurrences (all)	14 / 31 (45.16%) 47	10 / 59 (16.95%) 18	49 / 175 (28.00%) 99
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 7	2 / 59 (3.39%) 2	12 / 175 (6.86%) 21
Viral infection subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	0 / 59 (0.00%) 0	4 / 175 (2.29%) 4
Sinusitis subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	5 / 59 (8.47%) 6	5 / 175 (2.86%) 5
Varicella subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	2 / 59 (3.39%) 2	3 / 175 (1.71%) 3
Metabolism and nutrition disorders			
Iron deficiency subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	0 / 175 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	2 / 175 (1.14%) 2
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 59 (0.00%) 0	1 / 175 (0.57%) 1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 October 2016	Details were added regarding neurological examinations specified in the protocol; Urine and blood pregnancy tests were added to the schedule of assessments for both Part 1 and Part 2 of the study; Stopping rules for cohorts in the dose-escalation part of the study were changed to allow the decision to terminate a cohort to be made by the iDMC
07 March 2017	The randomization ratio was changed from 1:1 to 2 (active):1 (placebo), and the sample size increased to maintain the same statistical power; Subjects initially randomized to placebo were switched to active treatment after 12 months; Age group stratification was subdivided: in place of one group of subjects aged 6 to 17 years, two groups were specified, aged 6 to 11 and 12 to 17 years; A new market formulation was introduced; Clarification that following the dose selection for Part 2, data from the exploratory Part 1 of this study (and the Part 1 extension phase) could be locked at intervals in order to analyze and report the safety, PK/PD and exploratory efficacy of those subjects enrolled into Part 1 only, which does not impact the integrity of Part 2 of the study; Two new scales were added, the SMAIS and CGI-C; The respiratory measures MEP and MIP were added; Based on Study BP29840, no interaction with CYP3A inducers or inhibitors was expected; therefore, some prohibited drugs were removed from the exclusion criteria and prohibited therapy; A summary of Part 1 data was provided. The pivotal dose was incorporated into the protocol; PedsQL subject-reported outcome measurements were included in Part 1 for up to 12 months of risdiplam treatment; Home nursing visits were removed (for U.S. only) as these were not utilized by the sites except to deliver study drug. These visits were replaced with a study drug service; The age limit at time of randomization was clarified for the completion of pulmonary function testing required for the study
01 March 2019	Results from in vitro studies characterizing the inhibition of CYP3A4 by risdiplam were added. This inhibition has the potential to increase the concentration of concomitant medications predominantly metabolized by the CYP3A4 enzyme; Studies in animals have shown that risdiplam is teratogenic and fetotoxic. The "Background on RO7034067" and "Safety Precautions" sections were updated accordingly; Responder analyses for the Hammersmith Functional Motor Scale Expanded (HFMSSE) and Revised Upper Limb Module (RULM) were added as secondary objectives; The end of the study was revised. A subject's treatment in the open-label extension phase of the study may continue for 3 years. Thereafter, treatment will continue until the drug is available commercially in the subject's country. The end of the study is when the last patient completes 5 years into the study; An exclusion criterion was added for the use of inhibitors or inducers of FMO1 or FMO3. FMO1 and FMO3 inhibitors and inducers was added to the prohibited therapy section; Chronic treatment was defined as a minimum of 8 weeks to ensure that all sites in the study are applying the same definition;
01 March 2019	The permitted therapy section was updated to state that concomitant medications that are CYP3A4 substrates are permitted if required; however, as per usual clinical practice, potential toxicities should be monitored carefully, in particular for medications with a narrow therapeutic window; Adverse events of skin or subcutaneous reaction, pharyngeal/laryngeal or mucosal reaction, and clinically relevant retinal abnormalities on optical coherence tomography/fundus photography were removed from the list of non-serious adverse events of special interest (AESI) as the independent data monitoring committee (iDMC) provided independent safety surveillance; Blood samples for SMN protein every 26 weeks following the Week 104 visit were added in order to assess whether any increase in SMN protein observed in the first 104 weeks is sustained over the long term

22 June 2020	The number of ophthalmological assessments required during the open-label extension period was reduced. The study drug name was changed from RO7034067 to risdiplam. Cautionary language on the concomitant use of CYP3A4 substrates was removed. Given the absence of any risdiplam-induced ophthalmological findings to date, the frequency of ophthalmology assessments after completion of study visit Week 104 was reduced to every 6 months and intra ocular pressure assessment and fundus photography were removed from the schedule of assessments after completion of Week 104. The follow-up visits after study completion/early withdrawal visit were replaced with a phone call 30 days after this visit (i.e. at least 30 days after last dose of study medication) to capture adverse events. Risdiplam-related adverse events were not expected beyond this adverse event reporting period.
--------------	---

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported